Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus

Table 1

Patient demographics and disease characteristics of RA before abatacept treatment.

Case number	Sex	Age (year)	Duration of arthritis (month)	RF (U/mL)	ACPA (U/mL)	Erosion on X-ray typical for RA	TJC (/28)	SJC (/28)	Patient global VAS (mm)	Physician global VAS (mm)	DAS28; -ESR	MMP-3 (ng/mL)	Intra-articular; synovitis with PD signals	Teno-synovitis with PD signals	Predni-solone (mg/day)	DMARD/; immunosuppressant in combination	Previous DMARD/; immunosuppressant
1	F	29	38	459	110	(+)	16	10	60	73	7.02	116	(+)	(+)	0	MTX	Adalimumab
2	F	66	85	<5	<0.6	(+)	0	5	77	65	3.64	175	(+)	(−)	7	Tacrolimus	MTX
3	F	60	183	40	>100	(+)	5	11	48	49	4.11	87.6	(+)	(+)	8	Tacrolimus	MTX
4	F	58	163	<5	<0.6	(+)	0	12	51	43	4.11	106	(+)	(+)	5	MTX	None
5	F	53	23	<5	0.7	(+)	0	2	25	40	3.08	148	(+)	(+)	4	MTX	Etanercept
6	F	57	108	25	>100	(−)	9	17	66	73	6.42	160	(+)	(−)	2	Cyclosporin A	MTX

RA: rheumatoid arthritis; RF: rheumatoid factor; ACPA: anticitrullinated peptide antibody; TJC: tender joint count; SJC: swollen joint count; VAS: visual analogue scale; DAS: Disease Activity Score; ESR: erythrocyte sedimentation rate; MMP: matrix metalloproteinase; PD: power Doppler; SLE: systemic lupus erythematosus; DMARD: disease-modifying antirheumatic drug; F: female; MTX: methotrexate.